
Feature|Videos|July 7, 2025
Aligning Real-World Evidence with Payer Perspectives
Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.
Advertisement
Episodes in this series

The trust gap between real-world evidence (RWE)/data and randomized controlled trials is growing. This episode examines when each evidence type is appropriate, how to reduce perceived bias in RWE, and how payer context varies by geography and structure. Insights from academic and payer partnerships show how joint research can establish credibility and unlock market access.
Key discussion topics include:
- Strategies for reducing payer skepticism about real-world data.
- The influence of health system structure on RWE acceptance.
- Use cases for RWE in confirmatory versus primary evidence roles.
Advertisement
Related to this article

At LogiPharma USA 2026, Cold Chain Technologies' TJ Rizzo explains how gaps in end-to-end cold chain expertise create risk for advanced therapies.

Octapharma USA's Kerem Tokel explains how tariffs and DSCSA are affecting how stolen pharma loads are resold, and why partner SOPs matter.

At LogiPharma USA 2026, Mark Talens explains where pharma gains the most from shared distribution visibility.

In this week's Pharma Pulse, PhRMA sues to block CMS's GLOBE pricing model, WFS opens a temperature-controlled cargo terminal in Lyon and Bayer commits $2.2 billion to a new Ohio manufacturing site.

Freehand CEO Nitin Jayakrishnan explains why pharma manufacturers are trading long-term plans for operating models built to sense and pivot.

PhRMA's lawsuit argues CMS overstepped its demonstration authority by tying Medicare Part B rebates to international prices.

At LogiPharma USA 2026, Swisslog's Garrett Freeman explains how onshoring, geopolitical risk and a shifting product mix are driving supply chain automation.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why Securing Pharma Freight Starts With Broker and Carrier SOPs
2
Supply Chain Visibility Needs Context Before AI, Says PAXAFE’s Mark Talens
3
LogiPharma USA 2026: Where Cold Chain Expertise Gaps Become Product Risk
4
Pharma Pulse: PhRMA Sues to Block GLOBE Model and Bayer's $2.2B Ohio Site
5

